Keeping Track of the Most Recent Treatment Updates

There are a lot of treatment updates for various malignancies happening seemingly all at once. We had the chance to speak with Laura S. Wood, RN, MSN, OCN, for her take on why these updates are coming so rapidly.

At the 3rd Annual School of Nursing Oncology, Oncology Nursing News® had the chance to sit down with Laura S. Wood, RN, MSN, OCN, renal cancer research coordinator at the Cleveland Clinic Taussig Cancer Center and one of the co-chairs of the School of Oncology Nursing, and discuss why she believes there are currently so many updates for various malignancies and where these updates are going.


So, we're seeing quite a few updates in the treatment options for a variety of malignancies. That really goes back to better understanding the pathobiology of various cancers and understanding the role of the immune system and being able to target, and or reactivate, the immune system and recognizing that that plays a role in all different malignancies. And so, the clinical trial data has really matured and enrollment in clinical trials has increased our ability to answer those questions and identify those treatment options that are appropriate and those that are not appropriate for FDA approval and treatment.

Related Videos
Karyn Goodman
Grace Choong
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Paula Anastasia Emphasizes Importance of Genetic Testing in Selecting Maintenance
Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
Related Content
© 2023 MJH Life Sciences

All rights reserved.